Targeted Diagnostics and Therapeutics ("TDT") was founded in August 1994 to commercialize the proprietary platform technologies developed in the laboratories of Dr. Scott A. Waldman, M.D., Ph.D., at Thomas Jefferson University in Philadelphia, Pennsylvania. TDT entered into a long-term research agreement with Thomas Jefferson University, and funds continuing research and development efforts in the Waldman laboratories in exchange for worldwide exclusive rights to the platform technology and the intellectual property resulting from the sponsored research.

TDT's application of this technology to colorectal cancer is based upon Dr. Waldman's discovery of a unique cell surface receptor found exclusively on colorectal cancer cells and not on any normal or other cancer cells outside the gastrointestinal tract. This receptor provides an ideal marker for detecting colorectal cancer cells that have spread beyond the intestine. TDT's resultant molecular-based tests are so sensitive that they can detect a single cancer cell in 10 million normal cells.

Therefore, this technology will yield many applications for improving the management of cancer patients. In colorectal cancer, work is underway to develop:

in vitro
diagnostic to detect cancer cells in lymph nodes
Definitive detection of colorectal cancer metastases beyond the intestinal tract to improve the accuracy of disease staging

in vitro
diagnostic to detect circulating cancer cells in peripheral blood
Highly specific test to determine whether a patient has developed recurrent colorectal cancer

In vivo imaging agent

Identification and localization of metastatic tumors employing imaging techniques

In vivo targeted therapeutics Target chemotherapy agents to destroy only colorectal cancer cells, not normal cells or tissues